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ABSTRACT
Clinical isolates (n = 389) of methicillin-resistant Staphylococcus aureus (MRSA) recovered from 371
patients between January 2003 and June 2004 at the three major public hospitals on the island of Majorca,
Spain were studied. The clonal relatedness of MRSA isolates was determined by pulsed-ﬁeld gel
electrophoresis (PFGE) after digestion with SmaI. During the study period, MRSA was found in 31% of
patients with S. aureus-positive cultures. PFGE analysis identiﬁed three predominant clones, affecting
94% of the patients. The three clones had been detected since 1999 in one hospital, and were designated
as clones A, B and C. Whereas clones A and B (multidrug-resistant) were related to the two most
prevalent clones in Spain at this time, clone C was identical to EMRSA-15, currently one of the most
common MRSA clones in UK hospitals and also detected in other countries, but rarely in Spanish
hospitals. This imported epidemic clone was detected in c. 10% of patients admitted to one of the three
hospitals in 2002, but its prevalence has increased signiﬁcantly (32% of the patients investigated in the
three hospitals in the present study), and this clone also accounted for 44% of the isolates from non-
hospitalised patients. Even though EMRSA-15 showed the least multidrug resistance of the three major
clones, it was apparently more virulent, since it was associated signiﬁcantly (p 0.001) with bacteraemia,
and positive blood cultures were documented for 21% of the patients infected by this clone, compared
with only 10% and 7% of patients infected with clones A and B, respectively.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
strains were identiﬁed soon after the introduction
of methicillin into clinical practice [1,2]. Since the
ﬁrst outbreaks of infection caused by MRSA in
Europe during the early 1960s [3], this pathogen
has spread worldwide, not only throughout the
hospital environment, but also among community
patients without exposure to healthcare systems.
Furthermore, the incidence of MRSA is increas-
ing, despite the development of infection con-
trol programmes in many countries. Molecular
epidemiology studies have shown that the cur-
rent MRSA pandemic is the result of the global
dissemination of a few highly successful clones
[4,5].
In Spain, the ﬁrst nosocomial outbreak of this
pathogen was detected in 1981 [6,7], but MRSA
was not a serious problem until the ﬁrst outbreaks
were detected in major Spanish cities at the end of
1989 [8,9]. Most MRSA outbreaks in Spain
between 1989 and 1995 were caused by the
‘Iberian’ clone, which was ﬁrst detected in 1989
in Barcelona [10], and which showed resistance to
most antibiotic groups (i.e., macrolides, tetracy-
clines, aminoglycosides and quinolones). How-
ever, in the mid-1990s, this clone was
progressively supplanted by other MRSA clones
associated with less multidrug resistance [11,12].
A Spanish surveillance study performed in 2002
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showed a progressive increase in the proportion
of MRSA isolates (from 1.5% in 1986 to 31.2% in
2002), and an alarming number of methicillin-
resistant isolates were recovered from outpa-
tients; thus, while <5% of community-acquired
S. aureus isolates in 1994 were methicillin-resist-
ant, 17.8% were methicillin-resistant in 2002 [13].
The ﬁrst MRSA outbreak on the island of
Majorca was described in June 1999; since then
the epidemiology of MRSA infections has chang-
ed in terms of both clinical and microbiological
aspects. The aims of the present work were to
analyse recent data concerning the molecular
epidemiology and susceptibility of the different
MRSA clonal types circulating in Majorcan hos-
pitals, and to compare these results with those of
previous local and national studies in Spain, in
order to describe the evolution of the epidemi-
ology of this pathogen on Majorca in recent
years.
MATERIALS AND METHODS
Patients and clinical isolates
The study was carried out between January 2003 and June
2004 in the three main public hospitals that serve nearly all
the population of the island of Majorca, Spain: Hospital
Universitari Son Dureta (HUSD; 800 beds), which is the
tertiary reference hospital of the Balearic Islands; Hospital
Son Lla`tzer (330 beds); and Hospital de Manacor (200 beds).
Only the ﬁrst clinical isolate of MRSA (isolates from coloni-
sation studies were not included) from each patient was
included in the molecular epidemiology study, except for 18
patients who were admitted to two different hospitals at
different times, for whom the ﬁrst isolate from each admis-
sion was included. Types of clinical sample and hospital
wards were recorded for MRSA-positive patients. Isolates
were identiﬁed as S. aureus by standard microbiological
procedures [14].
Antimicrobial susceptibility testing
Susceptibilities to oxacillin, vancomycin, teicoplanin, cipro-
ﬂoxacin, erythromycin, clindamycin, gentamicin, mupirocin,
fusidic acid, rifampicin and trimethoprim–sulphamethoxazole
were determined by disk-diffusion according to CLSI recom-
mendations [15]. The breakpoints used for fusidic acid
(susceptible (S) ‡28 mm, intermediately-susceptible (I) 24–
27 mm, resistant (R) £23 mm) and mupirocin (S ‡14 mm, R
£13 mm) were those recommended by the disk manufacturer
(Rosco Diagnostica, Taastrup, Denmark). The classical pheno-
types of macrolide–lincosamide–streptogramin B (MLSB)
resistance were deﬁned as follows: constitutive (c)MLSB,
erythromycin- and clindamycin-resistant; inducible (i)MLSB,
erythromycin-resistant, with clindamycin resistance inducible
by erythromycin (presence of antagonism between the two
disks); M phenotype, erythromycin-resistant and clindamycin-
susceptible (absence of antagonism).
Molecular epidemiology studies
All MRSA isolates were characterised by macrorestriction
analysis of chromosomal DNA after SmaI digestion and
separation of the fragments by pulsed-ﬁeld gel electrophoresis
(PFGE) using a CHEF-DR III contour-clamped homogeneous
electric ﬁeld apparatus (Bio-Rad Laboratories, Richmond, CA,
USA), programmed at 200 V (6 V ⁄ cm) for 23 h, with switching
times ramped from 1 to 3 s. DNA fragments were visualised
by staining with ethidium bromide and photographed under
UV illumination, and were then interpreted following criteria
recommended previously [16]. Control MRSA strains com-
prised: the three major clones (designated A, B and C) detected
in previous studies at HUSD [17]; the two predominant MRSA
clones, designated P1 and Q1, found in a multicentre Spanish
study in 2004 [12]; the pandemic Iberian clone (ATCC BAA-44)
[18]; the Brazilian clone (ATCC BAA-43) [19]; the Hungarian
clone (ATCC BAA-39) [20]; the New York–Japan clone
(ATCC BAA-41) [21]; the paediatric clone (ATCC BAA-42)
[22]; and two isolates of EMRSA-15 (DEN4561 and HAR22)
[23,24]. The reference strain S. aureus NCTC 8325 [16] was
used as a molecular size standard to normalise the PFGE
proﬁles. The nomenclature for MRSA clones in the present
study was based on that established for previous collections
[17].
Data analysis
Statistical analysis of the categorical variables was performed
using Fisher’s exact test and SPSS software (SPSS Inc., Chicago,
IL, USA), with p <0.05 considered to be statistically signiﬁcant.
RESULTS
During the period of the study, 389 sequential
MRSA isolates (202 from HUSD, 154 from Hos-
pital Son Lla`tzer, 33 from Hospital de Manacor)
were recovered from 371 patients in the three
participating hospitals, representing 31% of the
patients with S. aureus-positive cultures. For 170
(46%) of the 371 patients, MRSA was isolated
from only one sample type, whereas it was
isolated from two or more sample types for 201
(54%) patients. The most frequent source of
MRSA was exudates, mainly wound infections,
ulcers and abscesses (49% of the patients), fol-
lowed by the respiratory tract (37%). MRSA-
positive blood cultures and intravenous catheters
were documented for 14% and 7% of the patients,
respectively.
Analysis of the PFGE patterns of the 389 MRSA
isolates revealed that 366 (94%) belonged to three
main clonal types (A, B and C) (Fig. 1). The
remaining 23 (6%) MRSA isolates had different
PFGE patterns, each being detected in <1.5% of
the patients, and were therefore considered to be
sporadic clones. Clone A accounted for 132 (34%)
isolates, clone B for 109 (28%) isolates, and clone
600 Clinical Microbiology and Infection, Volume 13 Number 6, June 2007
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 599–605
C for 125 (32%) isolates (Table 1). These major
clones were not related to any of the ﬁve previ-
ously described pandemic clones, including the
Iberian clone, but clones A and B have been
shown previously to be related to the two most
prevalent clones (clones P1 and Q1) found in
Spain at the present time. Clone C had a PFGE
pattern identical to that of the EMRSA-15 epi-
demic clone (Fig. 1). Four subtypes of this clone
(C1–C4) were detected (Fig. 1); the C1 subtype
showed a PFGE pattern identical to that of one of
the known EMRSA-15 control isolates (DEN4561),
and the C2 subtype was identical to the other
control isolate (HAR22).
All three major clones were detected in all three
participating hospitals, although with slight
differences among the different institutions
(Table 1). In HUSD, the most frequent clone was
clone B, isolated from 35% of patients with
MRSA-positive cultures (p 0.002 compared with
the other hospitals, 21%). In contrast, clone A,
detected in 42% of patients, was the most fre-
quent clone in Hospital Son Lla`tzer (p <0.001
compared with the other hospitals, 29%), and
clone C (52%) was the most frequent clone in
Hospital Manacor (p <0.001 compared with the
other hospitals, 30%).
Several interesting differences were observed
when the distributions of MRSA clones from
patients on different wards were compared
(Table 1). The prevalence of MRSA clone B was
signiﬁcantly higher among patients admitted to
intensive care units (ICUs) and surgical wards,
being isolated from 42% of all patients with
MRSA-positive cultures in ICUs, compared with
26% in non-ICU wards (p 0.003), and from 40% of
all patients with MRSA-positive cultures in surgi-
cal units (p <0.001). No signiﬁcant differences
were observed in terms of the distribution of clone
B in the ICUs of the three participating hospitals,
although most (93%) MRSA isolates from ICUs
were recovered from just two hospitals. Moreover,
the overall high prevalence (47%) of clone B
among patients in surgical wards was caused
largely by the contribution from a single hospital.
In contrast, clone C (EMRSA-15) was isolated
more frequently from non-hospitalised patients
(emergency room and outpatient departments),
being isolated from 44% of patients with MRSA-
positive cultures in these departments, compared
with 30% of hospitalised patients (p <0.001),
suggesting that this clone is widespread in the
community.
Interesting differences were also observed
when the different sources of infection were
compared (Table 1). Remarkably, the proportion
of clone C (EMRSA-15) among blood specimens
(52%) was signiﬁcantly higher (p <0.001) than
among other specimens (29%). Moreover, positive
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Fig. 1. SmaI macrorestriction patterns of clone A, clone B
and the four subtypes of clone C (C1–C4). Two isolates of
EMRSA-15 are included for comparison. Reference strain
NCTC 8325 was used as the molecular size standard.
Table 1. Distribution of the major methicillin-resistant
Staphylococcus aureus (MRSA) clones, grouped according
to the hospital, hospital department and source of isolation
Total MRSA
n (%)
Clone A
n (%)
Clone B
n (%)
Clone C
n (%)
Others
n (%)
Overall 389 (100) 132 (34) 109 (28) 125 (32) 23 (6)
Hospital
HUSD 202 (52) 63 (31) 70 (35) 57 (28) 12 (6)
Son Lla`tzer 154 (40) 64 (42) 34 (22) 51 (33) 5 (3)
Manacor 33 (8) 5 (15) 5 (15) 17 (52) 6 (18)
Departmenta
Medical wards 182 (46) 69 (38) 42 (23) 61 (33) 10 (6)
Surgical wards 75 (19) 22 (29) 30 (40) 17 (23) 6 (8)
ICU 43 (11) 14 (32) 18 (42) 11 (26) 0 (0)
Non-hospitalised 66 (16) 17 (26) 14 (21) 29 (44) 6 (9)
Source of isolationa
Blood 51 (13) 13 (25) 8 (15) 27 (52) 3 (5)
Respiratory tract 137 (35) 53 (38) 43 (31) 36 (26) 4 (2)
Exudates 190 (48) 61 (32) 53 (27) 64 (33) 12 (6)
aData for isolates from other or unknown departments (n = 23) and sources of
isolation (n = 11) not shown.
HUSD, Hospital Universitari Son Dureta; ICU, intensive care unit.
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blood cultures were documented for 21% of the
patients who were positive for this clone, com-
pared with 9% of patients positive for other clones
(p 0.001). The percentages of patients with posi-
tive blood cultures who were infected by the two
other major clones (A or B) were only 10% and
7%, respectively.
Table 2 shows the antimicrobial resistance rates
among all 389 MRSA isolates, as well as for the
different clonal types. Overall, the MRSA isolates
were uniformly susceptible to vancomycin and
teicoplanin, and showed low rates of resistance to
mupirocin (5%), fusidic acid (4%), rifampicin
(2%) and trimethoprim–sulphamethoxole (1%).
However, since disk-diffusion was used to test
susceptibility, the presence of isolates with low-
level glycopeptide resistance cannot be ruled out.
Most (96%) isolates were resistant to ciproﬂoxa-
cin, whereas resistance to erythromycin (70%),
clindamycin (55% with cMLSB; 15% with iMLSB)
and gentamicin (33%) was more variable. Clone B
was associated with the highest rates of multi-
resistance, showing 100% resistance to cipro-
ﬂoxacin (p 0.004 compared with other clones),
95% to erythromycin (p <0.001), 92% to clinda-
mycin, plus an additional 3% with the iMLSB
phenotype (p <0.001), and 93% to gentamicin
(p <0.001). In contrast, clone C (EMRSA-15)
showed the lowest rates of multiresistance among
the three major clones, and a signiﬁcantly lower
level (5%) of resistance to gentamicin (p <0.001).
Interestingly, clone C frequently showed the
iMLSB phenotype (40% of all clone C isolates,
including 67% of those resistant to erythromycin),
whereas this phenotype was infrequent among
the other clonal types (4% of all the non-clone C
isolates, including 5% of those resistant to eryth-
romycin) (p <0.001).
DISCUSSION
During the last four decades, methicillin resistance
in S. aureus has been a problem of global dimen-
sions, affecting mainly hospitalised patients,
although MRSA has also emerged as a commu-
nity-acquired pathogen in recent years. The
prevalence of MRSA in Europe follows a north-
to-south gradient, being lowest in Scandinavian
countries (<2%) and highest in southern Europe,
e.g., Greece, Italy, France, Spain and Portugal
(30–60%) [25]. In Spain, the prevalence of MRSA
has increased continuously since 1986 (1.5%),
reaching 31% in 2002 [13]. Also, as in other
countries, MRSA infections originating in the
community are no longer infrequent, accounting
for 18% of community-acquired S. aureus infec-
tions during 2002 [13].
Although the prevalence (31%) of MRSA
revealed in Majorcan hospitals by this study is
very similar to that reported in the rest of Spain, the
molecular studies revealed remarkable differences
concerning the epidemiology of this pathogen on
the island. In addition to the two predominant
MRSA clones found in Spanish hospitals, a high
prevalence (32%) of the epidemic clone EMRSA-15
was found. Clone C, now classiﬁed as EMRSA-15,
was already present in Majorca in 1999 (10% of
MRSA-positive patients), but its prevalence has
increased dramatically in recent years, so that it
accounted for almost one-third of patients with
MRSA who attended Majorcan hospitals in the
present study. EMRSA-15 is the most frequent
clone isolated in UK hospitals [26], and has also
been detected in Germany [27], Finland, Sweden,
Belgium [28], Portugal [29], Australia [30] andNew
Zealand [31]. This clone was reported for the ﬁrst
time in Spain at a teaching hospital in Tenerife
(Canary Islands) [32], but the overall prevalence of
EMRSA-15 in Spanish hospitals was found to be
low (0.7%) in a large study involving >2000MRSA
isolates recovered between 1996 and 2002 from 110
Spanish hospitals [11].
The differential high prevalence of EMRSA-15
in Majorcan hospitals may be linked to the fact
that the island is a frequent tourism destination
(as is the Canary Islands) for individuals from
countries with a high prevalence of this clone,
Table 2. Antibiotic resistance rates among 389 methicillin-
resistant Staphylococcus aureus (MRSA) isolates from
Majorca, Spain
Antibiotic
Total MRSA
(n = 389)
n (%)
Clone A
(n = 132)
n (%)
Clone B
(n = 109)
n (%)
Clone C
(n = 125)
n (%)
Others
(n = 23)
n (%)
Ciproﬂoxacin 373 (96) 128 (97) 109 (100) 122 (98) 14 (61)
Gentamicin 128 (33) 17 (13) 101 (93) 6 (5) 4 (17)
Trimethoprim–
sulphamethoxazole
4 (1%) 0 3 (3%) 0 1 (4%)
Vancomycin 0 0 0 0 0
Teicoplanin 0 0 0 0 0
Rifampicin 9 (2) 5 (4) 3 (3) 1 (1) 0
Mupirocin 21 (5) 10 (8) 11 (10) 0 0
Fusidic acid 16 (4) 6 (4) 2 (2) 7 (6) 1 (4)
Erythromycin 272 (70) 83 (63) 104 (95) 75 (60) 10 (43)
Clindamycin
cMLSB 212 (55) 78 (59) 100 (92) 25 (20) 9 (39)
iMLSB 60 (15) 5 (4) 4 (4) 50 (40) 1 (4)
cMLSB, constitutive macrolide–licosamide–streptogramin B (MLSB) resistance;
iMLSB, inducible MLSB resistance.
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which perhaps highlights the importance of travel
in the international spread of multiresistant path-
ogens. The prevalence of EMRSA-15 was even
higher among non-hospitalised patients (44% vs.
30%), suggesting that, particularly for this clone,
the ﬂux was mainly from the community to the
hospital setting, and not the other way around (as
might be expected). The increase in MRSA infec-
tions in healthcare institutions other than hospi-
tals could also contribute to this inverted ﬂux. A
study of patients with decubitus ulcers in a
geriatric institution in Majorca between January
2000 and June 2002 revealed a very high preval-
ence of MRSA (70%), and the proportion of clone
C (EMRSA-15) was already high (30%) during
that period compared with 10% in the hospital
setting [33].
A further interesting ﬁnding associated with
EMRSA-15 is that, despite showing the lowest
frequency of multidrug resistance among the
three major clones, it was apparently more viru-
lent, since it was associated signiﬁcantly with
bacteraemia. Positive blood cultures were docu-
mented for 21% of the patients infected by this
clone, compared with <10% for the other major
clones. Analysis of the interplay among patho-
genicity, epidemicity and antibiotic resistance is a
key element in understanding the evolution
of microbial pathogens [34]. Several lines of
evidence support the hypothesis of an inverse
relationship between antibiotic resistance
and epidemicity and pathogenicity in MRSA.
Displacement of multidrug-resistant MRSA
clones by more susceptible lineages has been
described in recent years and, particularly for
gentamicin resistance, has been found to be
linked with increased ﬁtness of the susceptible
lineages and a reduction in the use of gentamicin
[12,35–38]. The type of staphylococcal chromoso-
mal cassette (SCC) mec complex could also play a
role, since the SCCmec type showing the most
efﬁcient dissemination (SCCmecIV) is also associ-
ated with reduced antimicrobial resistance
[39,40]. Both gentamicin susceptibility (as shown
in this study) and the presence of SCCmecIV [5]
are characteristics of EMRSA-15. Nevertheless,
the possible association between EMRSA-15 and
bacteraemia, and whether this is related to
reduced antimicrobial resistance, needs to be
conﬁrmed in clinical studies designed with this
speciﬁc aim. There are important clinical impli-
cations, in that bacteraemia caused by MRSA is
associated with increased mortality compared
with that caused by methicillin-susceptible strains
[41].
In conclusion, widespread dissemination of the
epidemic EMRSA-15 clone was found throughout
Majorca, and this clearly differs from the situation
documented in mainland Spanish hospitals. In
addition, a statistically signiﬁcant association was
found between this clone and lower antimicrobial
resistance rates, non-hospitalised patients and
bacteraemia.
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